BioSpace News Archive

The deal, which will last several years, has Tango performing target discovery and validation. Gilead will be able to option rights to up to five targets that come out of Tango’s work.

Fall is in full swing, but not falling short of jobs. Check out the top companies who are looking for candidates like you right now!

With any luck, each job will have great bosses, as unlikely as that seems. But even if your bosses aren’t necessarily great, you can probably learn something from each of them. Here are a dozen lessons you can learn from the best bosses.

Adagene, Inc. today announced the dosing of its first patient in its Phase I trial in American for its lead product ADG-106, a fully human agonistic monoclonal antibody (mAb) targeting a novel epitope of CD137.

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, and Thomas Castellano, Vice President Finance, Investor Relations and Treasurer will present at the following conferences in the coming weeks.

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the third quarter ended September 30, 2018.

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced positive topline data from its Phase 1 trial of Collagenase Clostridium Histolyticum

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that Melvin K. Spigelman, M.D., who has served as an Independent Director of Synergy since August 2008, will now assume the role of Chairman of the Board, effective immediately.

CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the third quarter ended September 30, 2018.

Open Enrollment for 2019 health coverage through the Health Insurance Marketplace begins Nov. 1